|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/15 | |
| A61K 31/70 | |||
| A61K 48/00 | |||
| A61K 9/08 | |||
| A61P 31/12 | |||
| A61P 31/00 |
| (11) | Number of the document | 2646052 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11845053.5 |
| Date of filing the European patent application | 2011-12-02 | |
| (97) | Date of publication of the European application | 2013-10-09 |
| (45) | Date of publication and mention of the grant of the patent | 2017-03-29 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/063037 |
| Date | 2011-12-02 |
| (87) | Number | WO 2012/075376 |
| Date | 2012-06-07 |
| (30) | Number | Date | Country code |
| 419020 P | 2010-12-02 | US |
| (72) |
COFFEY, Matthew C., CA
SERL, Sarah, CA
PAVLIV, Leo, US
|
| (73) |
Oncolytics Biotech Inc.,
Suite 210 1167 Kensington Crescent N. W., Calgary, AB T2N 1X7,
CA
|
| (54) | LYOPHILIZED VIRAL FORMULATIONS |
| LYOPHILIZED VIRAL FORMULATIONS |